Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. - Wikidata - awgldk - TriplyDB

Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

http://www.wikidata.org/entity/Q34301234

about

Cell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine Platform CryoEM structures of membrane pore and prepore complex reveal cytolytic mechanism of Pneumolysin.Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4.The impact of pneumolysin on the macrophage response to Streptococcus pneumoniae is strain-dependent.Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge Monocytes regulate the mechanism of T-cell death by inducing Fas-mediated apoptosis during bacterial infection Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives.Bacterial cytolysin during meningitis disrupts the regulation of glutamate in the brain, leading to synaptic damage.Pneumolysin with low hemolytic activity confers an early growth advantage to Streptococcus pneumoniae in the blood.Changes in astrocyte shape induced by sublytic concentrations of the cholesterol-dependent cytolysin pneumolysin still require pore-forming capacity.The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model Engineered nanoparticles mimicking cell membranes for toxin neutralization.Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury Crystal structure of Streptococcus pneumoniae pneumolysin provides key insights into early steps of pore formation.A biomimetic nanosponge that absorbs pore-forming toxins Direct transmembrane interaction between actin and the pore-competent, cholesterol-dependent cytolysin pneumolysin Red Blood Cell Susceptibility to Pneumolysin: CORRELATION WITH MEMBRANE BIOCHEMICAL AND PHYSICAL PROPERTIES.Protection from Streptococcus pneumoniae keratitis by passive immunization with pneumolysin antiserum.A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.Nanoparticle-detained toxins for safe and effective vaccination.Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen.Cord blood Streptococcus pneumoniae-specific cellular immune responses predict early pneumococcal carriage in high-risk infants in Papua New Guinea.Otitis-Prone Children Produce Functional Antibodies to Pneumolysin and Pneumococcal Polysaccharides.Mucosal immunization with recombinant fusion protein DnaJ-ΔA146Ply enhances cross-protective immunity against Streptococcus pneumoniae infection in mice via interleukin 17A.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.Current status and perspectives on protein-based pneumococcal vaccines.Streptococcal toxins: role in pathogenesis and disease.FMS-like tyrosine kinase 3 ligand treatment of mice aggravates acute lung injury in response to Streptococcus pneumoniae: role of pneumolysin.Detoxified pneumolysin derivative Plym2 directly protects against pneumococcal infection via induction of inflammatory cytokines.Pneumolysin Mediates Platelet Activation In Vitro.Pneumolysin activates neutrophil extracellular trap formation.A comparison of pneumolysin activity and concentration in vitro and in vivo in a rabbit endophthalmitis model.Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence.Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease.Identification of a secreted cholesterol-dependent cytolysin (mitilysin) from Streptococcus mitis.Activation of memory Th17 cells by domain 4 pneumolysin in human nasopharynx-associated lymphoid tissue and its association with pneumococcal carriage.A Novel Biomimetic Nanosponge Protects the Retina from the Enterococcus faecalis Cytolysin.Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

P2860

Q26784233-8B3746D8-BCD3-41CC-921B-7B0196FD4F2D Q30152651-60FF12DC-CDC0-48B2-9453-452017934F46 Q33601853-BF683CBE-7A59-4B2B-8B66-A3694D9C04A0 Q33675920-DFC486D7-F379-4B3B-8E7F-173B2775EE41 Q33785689-5C0AAA67-41E0-4C72-BF18-4AE40150EC48 Q34020348-4D763117-9768-4BBA-8440-3F89078C0892 Q34057765-23E69813-4F1F-47F7-9FCE-C504D598ABBF Q34350904-F9540030-7358-4231-A703-C3B746D5A52D Q34637890-F0D0A0DB-84EE-481B-98D7-F47014FEBAE1 Q34778472-6FC44515-541F-4944-815C-63E4C1AF2601 Q35272956-2DE0E2A1-AB5E-4904-9042-FB39852ABF41 Q35534472-0C3B6668-E74F-4219-8D2F-065B28458F88 Q35623322-F482B9AC-15CB-4C6A-A2B5-5F97CE6DA29B Q35991625-134FD0D9-7533-4AD7-8950-07D06BAD1B57 Q36018158-48408737-E202-4C59-B526-7A7419653439 Q36099951-55E6E363-48AD-4A02-8909-193475B700E3 Q36828355-3FB41881-A3A0-49D5-9E16-7C9D6708EE9D Q36860052-29FD87D8-2B19-4D57-8F4F-873B23B57EBF Q36876211-B3624DC1-59B1-43C1-BC70-D51694BFE175 Q37079291-2DBF86A5-A65B-4898-93A6-7514E16C4D1D Q37333825-76D439C1-A3A9-4CE5-82C5-C30C0C38B47A Q37426321-E5E3CC3E-B673-4FD9-9319-899E825714CE Q37619137-D7C0E277-7F2D-479D-8BD6-1EA71B62FE10 Q37622565-E78D0403-ED58-4261-9A91-15C6418A2A05 Q37683735-3DF6E2C8-49EC-460F-A064-00519F291C4D Q37713240-1073CE41-FE1A-407C-BB21-3AEF05A7CB7E Q38082673-4E95D02E-F0DE-4DA0-A79A-8D75427446CE Q38124921-AC90444F-7B72-4468-AF41-CE6281BCC251 Q38598360-9493017B-5E1E-4440-BEC3-C3500349D6AF Q38923919-85AEE74A-DD8D-43F4-AAC7-E057B11DE27B Q38975558-0DE8AE41-D5B1-45B9-B781-B332F675BA9B Q40669297-0B05B7CF-9A5E-4D79-B501-97190E523577 Q40839011-0CF06AA9-8843-45DD-AB98-0C703EBA4A7E Q41279007-4B7CEDB9-6A65-4F21-9034-D559F5E1F1E4 Q42638233-EA6E9198-F52A-4FC3-AF56-900AC6E36AFF Q42708867-B82C2779-0666-4915-861B-AE7FC70C366F Q42957216-73FC05BF-93B7-4DEF-8CCA-20DC99A0A3C1 Q43519933-5D13D5E9-A0C0-42CA-99C8-C338EAB367A0 Q46189476-137A7B91-5C77-474F-86DF-076AC6A20748 Q52365761-00430DCE-4CFB-4CF5-9706-D70210C83BBC

P2860

Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

http://www.wikidata.org/entity/Q34301234

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Construction and immunological ...... future pneumococcal vaccines.

@ast

Construction and immunological ...... future pneumococcal vaccines.

@en

Construction and immunological ...... future pneumococcal vaccines.

@nl

type

label

Construction and immunological ...... future pneumococcal vaccines.

@ast

Construction and immunological ...... future pneumococcal vaccines.

@en

Construction and immunological ...... future pneumococcal vaccines.

@nl

prefLabel

Construction and immunological ...... future pneumococcal vaccines.

@ast

Construction and immunological ...... future pneumococcal vaccines.

@en

Construction and immunological ...... future pneumococcal vaccines.

@nl

P1433

Q34301234-2EB76414-879D-42FF-85FC-D8C7496B5BF3

P1476

Q34301234-40AB783F-FDAC-46A4-A652-AF66F90B242D

P2093

Q34301234-154D5628-ECFF-4F26-9BFA-169C797CE84E

Q34301234-30355423-4BC2-427B-94D3-7A11A8752C7D

Q34301234-6DF68296-9D29-4725-B4BE-98E0ED03533E

Q34301234-C399E98D-7C12-4DE9-B3E3-525EB6528FFF

Q34301234-C6767609-E174-4F07-B2D8-EBDBD6ADE73A

Q34301234-D38B0C28-91CB-4EE3-9140-9A9F4EB42043

Q34301234-D693E11C-50A7-4854-858B-CAB00589CA96

P2860

Q34301234-09624CFD-7462-4118-A7B9-E8B8F9CC9BFB

Q34301234-0D73ACBC-2292-4D23-8CCD-1547C2A89C62

Q34301234-0DE687F4-42A3-4B5F-9ADF-770EE3957DB2

Q34301234-1CFEFB15-E071-4347-A1E7-C3D5D8E41D63

Q34301234-289648CB-4B1B-402D-9EE4-548C90A63C5C

Q34301234-2F1B6CF5-E865-48AF-8A47-4F7899A3EB2A

Q34301234-33F08DE9-E993-43BD-A888-B150DB280519

Q34301234-3ECBCD3A-EB26-4641-9145-3D548F914CA1

Q34301234-48A3DE70-E1FE-4957-BEA4-7A7DDF46AB87

Q34301234-548BF08C-8B79-49E4-93D1-BF020135C4AE

P304

Q34301234-D271552A-2A37-4DB7-8100-4D9F2F006C45

P31

Q34301234-E39FB883-7FAB-47D3-9638-3BB31879B0B2

P356

Q34301234-616866CF-28CD-4EF7-9478-869893DF52E8

P407

Q34301234-85B3E15F-D40F-48A1-ADAF-015392F735ED

P433

Q34301234-9C39E276-4FF1-47F9-98DB-888277B905DE

P478

Q34301234-661649A6-0500-413D-AD38-BEB89360E9BF

P577

Q34301234-0B5C5681-840A-4066-B193-F18290FBAD2B

P5875

Q34301234-0611AAA6-A7FE-4AFE-97FD-8337134EAFFD

P698

Q34301234-D28F5F91-A456-4275-983E-FE48ECF1394E

P921

Q34301234-26B8F3C8-9B4E-4BC2-9939-DD26599434B9

P932

Q34301234-CC3C37D4-51AD-4119-B5F8-B20B261BC36D

P356

IAI.74.1.586-593.2006

P1433

Infection and Immunity

P1476

Construction and immunological ...... future pneumococcal vaccines.

@en

P2093

Alison R Kerr

http://www.w3.org/2001/XMLSchema#string

Dai-Fang Liu

http://www.w3.org/2001/XMLSchema#string

Deborah A Dilts

http://www.w3.org/2001/XMLSchema#string

Gavin K Paterson

http://www.w3.org/2001/XMLSchema#string

Gill R Douce

http://www.w3.org/2001/XMLSchema#string

Lea-Ann S Kirkham

http://www.w3.org/2001/XMLSchema#string

Tim J Mitchell

http://www.w3.org/2001/XMLSchema#string

P2860

Redefining cholesterol's role in the mechanism of the cholesterol-dependent cytolysins

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Structure of a cholesterol-binding, thiol-activated cytolysin and a model of its membrane form

Monomer-monomer interactions drive the prepore to pore conversion of a beta-barrel-forming cholesterol-dependent cytolysin.

The cholesterol-dependent cytolysins.

Essential role of domain 4 of pneumolysin from Streptococcus pneumoniae in cytolytic activity as determined by truncated proteins.

Assembly mechanism of the oligomeric streptolysin O pore: the early membrane lesion is lined by a free edge of the lipid membrane and is extended gradually during oligomerization.

Mapping of immunoreactive sites of pneumococcal pneumolysin by use of synthetic peptides.

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

P304

586-593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.74.1.586-593.2006

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7401962

http://www.w3.org/2001/XMLSchema#string

P698

16369015

http://www.w3.org/2001/XMLSchema#string

P921

P932

1346677

http://www.w3.org/2001/XMLSchema#string